- /
- Supported exchanges
- / US
- / ENTA.NASDAQ
Enanta Pharmaceuticals Inc (ENTA NASDAQ) stock market data APIs
Enanta Pharmaceuticals Inc Financial Data Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enanta Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Enanta Pharmaceuticals Inc data using free add-ons & libraries
Get Enanta Pharmaceuticals Inc Fundamental Data
Enanta Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 65 258 K
- EBITDA: -53 819 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Enanta Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-16
- EPS/Forecast: -0.83
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enanta Pharmaceuticals Inc News
New
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.87 per share a year ago. These fig...
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year a...
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
WATERTOWN, Mass., October 28, 2026--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections ...
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) shares rallied 5.2% in the last trading session to close at $14.06. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.